[go: up one dir, main page]

WO2003013598A3 - Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases - Google Patents

Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases Download PDF

Info

Publication number
WO2003013598A3
WO2003013598A3 PCT/US2002/025126 US0225126W WO03013598A3 WO 2003013598 A3 WO2003013598 A3 WO 2003013598A3 US 0225126 W US0225126 W US 0225126W WO 03013598 A3 WO03013598 A3 WO 03013598A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
bacteria
plant
veterinary
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/025126
Other languages
French (fr)
Other versions
WO2003013598A2 (en
Inventor
Dominic M K Lam
Fanya Zeng
Frederick C Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2003013598A2 publication Critical patent/WO2003013598A2/en
Publication of WO2003013598A3 publication Critical patent/WO2003013598A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The anti-pathogen vaccine of the present invention is produced in recombinant bacteria and/or transgenic plants and then administered through standard vaccine introduction method or through standard vaccine introduction method or through the oral administration. A DNA sequence encoding for the expression of an antigen of a pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a bacterial or transgenic plant. Preferably, a foreign gene is expressed in a protion of the plant or bacteria, and all or part of the antigen expressing plant or bacteria used for vaccine administration. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, or the bacteria administered orally.
PCT/US2002/025126 2001-08-09 2002-08-08 Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases Ceased WO2003013598A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31110601P 2001-08-09 2001-08-09
US60/311,106 2001-08-09

Publications (2)

Publication Number Publication Date
WO2003013598A2 WO2003013598A2 (en) 2003-02-20
WO2003013598A3 true WO2003013598A3 (en) 2004-01-08

Family

ID=23205432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025126 Ceased WO2003013598A2 (en) 2001-08-09 2002-08-08 Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases

Country Status (1)

Country Link
WO (1) WO2003013598A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220737B2 (en) 2003-04-27 2015-12-29 Protalix Ltd. Plant cell culture expressing human lysosomal proteins and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201420B1 (en) * 2002-12-04 2009-04-30 Inst Biotechnologii I Antybiot Chimeric protein, sequence, construction, vegetable cell, method of obtaining chimeric protein and transgenic plant, application of transgenic plant and chimeric protein
PL199190B1 (en) * 2002-12-31 2008-08-29 Inst Biotechnologii I Antybiot Inclusion bodies as antigenes in nutritional immunization of animals
ATE468390T1 (en) 2004-10-13 2010-06-15 Protalix Ltd SYSTEM AND METHOD FOR PRODUCING ANTIBODIES IN PLANT CELL CULTURE
WO2007010533A2 (en) * 2005-07-18 2007-01-25 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
CA2685701C (en) 2007-05-07 2019-01-15 Protalix Ltd. Large scale disposable bioreactor
CA2878862C (en) * 2012-07-13 2023-01-10 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
US20140096285A1 (en) * 2012-10-02 2014-04-03 The Board Of Trustees Of The University Of Illinois Soybean-based porcine reproductive and respiratory syndrome virus vaccine and methods for making and using the same
CN107109420A (en) 2014-07-21 2017-08-29 诺华股份有限公司 Cancer Therapy Using CLL-1 Chimeric Antigen Receptor
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020135A1 (en) * 1993-03-04 1994-09-15 Edible Vaccines Inc. Vaccines expressed in plants
WO1999008706A1 (en) * 1997-08-14 1999-02-25 Commonwealth Scientific And Industrial Research Organisation Recombinant porcine adenovirus vector
EP1293573A2 (en) * 2001-09-18 2003-03-19 Maltagen Forschung GmbH Process for producing a marker-vaccine against a mammalian virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020135A1 (en) * 1993-03-04 1994-09-15 Edible Vaccines Inc. Vaccines expressed in plants
WO1999008706A1 (en) * 1997-08-14 1999-02-25 Commonwealth Scientific And Industrial Research Organisation Recombinant porcine adenovirus vector
EP1293573A2 (en) * 2001-09-18 2003-03-19 Maltagen Forschung GmbH Process for producing a marker-vaccine against a mammalian virus

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHAN CAROL W M ET AL: "Expression of Hog Cholera Virus E2 in transgenic Arabidopsis.", PLANT BIOLOGY (ROCKVILLE), vol. 2002, 2002, Annual Meeting of the American Society of Plant Biologists on Plant Biology;Denver, CO, USA; August 03-07, 2002, 2002, pages 57, XP002250044 *
DANIELL H ET AL: "MEDICAL MOLECULAR FARMING: PRODUCTION OF ANTIBODIES, BIOPHARMACEUTICALS AND EDIBLE VACCINES IN PLANTS", TRENDS IN PLANT SCIENCE, ELSEVIER SCIENCE, OXFORD, GB, vol. 6, no. 5, May 2001 (2001-05-01), pages 219 - 226, XP001037864, ISSN: 1360-1385 *
HULST M M ET AL: "Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 67, no. 9, 1 September 1993 (1993-09-01), pages 5435 - 5442, XP002080070, ISSN: 0022-538X *
KIM HYUNSOON ET AL: "Expression of hog cholera virus in transgenic potato plants.", PLANT BIOLOGY (ROCKVILLE), vol. 2001, 2001, Joint Annual Meetings of the American Society of Plant Biologists and the Canadian Society of Plant Physiologists;Providence, Rhode Island, USA; July 21-25, 2001, pages 142, XP001161300 *
LAFAYETTE PETER R ET AL: "Engineering soybeans for the production of edible vaccines for poultry.", PLANT BIOLOGY (ROCKVILLE), vol. 2000, 2000, Annual Meeting of the American Society of Plant Physiologists;San Diego, California, USA; July 15-19, 2000, pages 138, XP002250043 *
PLANA DURAN ET AL: "Baculovirus expression of proteins of Reproductive and Respiratory Syndrome Virus strain Olot/91. Involvement of ORF3 and ORF5 proteins in protection", VIRUS GENES, KLUWER ACADEMIC PUBLISHERS, BOSTON, US, vol. 14, no. 1, 1997, pages 19 - 29, XP002103647, ISSN: 0920-8569 *
STREATFIELD S J ET AL: "Plant-based vaccines: unique advantages", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 17-19, 21 March 2001 (2001-03-21), pages 2742 - 2748, XP004231106, ISSN: 0264-410X *
TUBOLY T ET AL: "Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 19, April 2000 (2000-04-01), pages 2023 - 2028, XP004202498, ISSN: 0264-410X *
VAN GENNIP A H G P ET AL: "Chimeric classical swine fever viruses containing envelope protein E or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 4-5, 15 October 2000 (2000-10-15), pages 447 - 459, XP004218115, ISSN: 0264-410X *
VAN RIJN P A ET AL: "An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV)", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 5, February 1999 (1999-02-01), pages 433 - 440, XP004153825, ISSN: 0264-410X *
WIGDOROVITZ A ET AL: "Induction of a Protective Antibody Response to Foot and Mouth Disease Virus in Mice Following Oral or Parenteral Immunization with Alfalfa Transgenic Plants Expressing the Viral Structural Protein VP1", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 255, no. 2, 15 March 1999 (1999-03-15), pages 347 - 353, XP004440022, ISSN: 0042-6822 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220737B2 (en) 2003-04-27 2015-12-29 Protalix Ltd. Plant cell culture expressing human lysosomal proteins and uses thereof

Also Published As

Publication number Publication date
WO2003013598A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
RU2446208C2 (en) Application and method for preventing and treating caries caused by mutans streptococci different from streptococcus mutans
JP5143559B2 (en) Means and methods for preventing and / or treating caries
CN104277998B (en) Use and method for preventing and/or treating oral malodor
WO2003013598A3 (en) Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
EA200900180A1 (en) RECOMBINANT MODIFIED ANKARA OSPOVACCINE VIRUS (MVA), EXPRESSING HOMOLOGICAL SEQUENCE, BUILT INTO THE POXVIRAL GENE
WO2003029401A3 (en) Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
TW202310869A (en) Composition comprising superoxide dismutase and/or bacillus strain spores, and uses thereof for improving oral health
RU2002112327A (en) LANTIBIOTIC
TW200407426A (en) Vaccines
KR20230066660A (en) Periodontitis vaccine and related compositions and method of use
RU2745626C1 (en) Method of creating a live vaccine against covid-19 based on the probiotic strain enterococcus faecium l3 and a live vaccine enterococcus faecium l3-pentf-covid-19
TW202320829A (en) Combined use for improving oral health of aucuba japonica extracts and compositions comprising superoxide dismutase and/or bacillus strain spores
CN107501414A (en) Streptococcus mutans CAT SYI antigens and antibody
CN102772792B (en) Vaccine for preventing dental caries and preparation method thereof
TW202448486A (en) Use of nucleotides of fermented lactobacillus GM-090 for preparing pharmaceutical compositions for regulating immunity
KR20140130944A (en) Live vaccine composition comprising attenuated Salmonella mutants for preventing progressive atrophic rhinitis and pneumonic pastuellosis
TWI434852B (en) Peptide for modulating the immune responses of osteichthyes and applications in relative to the same
Lam et al. Vaccines expressed in plants
Kara et al. Identification of elicitor-induced cytochrome P450s of Astragalus chrysochlorus using targeted differential display

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP